(Adds details on drug, share movement)
March 22 (Reuters) - Drugmaker AbbVie Inc said on Thursday it would not seek accelerated approval for its experimental lung cancer treatment based on the results from a mid-stage study, sending its shares down 6 percent in premarket trading.
The study tested the company's Rova-T as a treatment for patients with small cell lung cancer who failed to respond to at least two prior regimens.
The drug is central to AbbVie's push to strengthen its cancer portfolio and reduce reliance on blockbuster Humira, which currently makes up about two-thirds of overall sales.
Late-stage trials testing the drug as a treatment for patients in the earlier stages of the disease will continue, the company said.
"Although the results from the study were not what we hoped for, we look forward to receiving data from the ongoing Phase 3 studies in the first- and second-line settings," said Mike Severino, the company's chief scientific officer and executive vice president of research and development.
AbbVie shares were down 5.75 percent at $106. (Reporting by Tamara Mathias in Bengaluru; Editing by Anil D'Silva)